zenodoopen
Figure 2 in Treatment of canine sarcoptic mange with afoxolaner (NexGard ) and afoxolaner plus milbemycin oxime (NexGard Spectra ) chewable tablets: efficacy under field conditions in Portugal and Germany
Figure 2. Dog with sarcoptic mange pre-treatment (first row pictures), and one month (second row pictures) and two months (third row pictures) after initiation of treatment with NexGard Spectra®.
ShareScore
40/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 8
- Harmonization
- 4
- Access
- 20
- Reuse readiness
- 8
- Engagement
- 0